AI-Driven Risk Prediction for Breast, Prostate and Pancreatic CancersTOKYO, Dec. 05, 2025 (GLOBE NEWSWIRE) -- A.D.A.M. Innovations Co. (Japanese Name:…
Phase 2 clinical trial initiated to evaluate SEMA3A mAb as potential treatment for Alport syndromeMilestone payment to Evotec expected upon…
MENLO PARK, Calif. and CINCINNATI, Dec. 3, 2025 /PRNewswire/ -- MyOme, a leading clinical whole-genome testing and polygenic risk modelling…
“The quarter reflects broad growth across all verticals, expanding VSDHOne adoption, and strategic investments aimed at supporting margin improvement and…
New resource provides clear guidance on insurance, financing, grants, and medication savings programs to make family building more accessibleNORWALK, Conn.,…
LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from…
New whole-genome test uncovers hidden genetic risk beyond traditional screening, empowering earlier and more precise care for millions of men.…
SUZHOU, China, Nov. 19, 2025 /PRNewswire/ -- Data from the keynote report at the 18th Annual Conference of the Chinese…
SCOTTSDALE, Ariz., Nov. 14, 2025 /PRNewswire/ -- Tulsa Fertility Center, a leading provider of reproductive medicine and one of Oklahoma's…
SALT LAKE CITY, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing…